Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses grows, but more slowly than its trailing trend
Q2 FY2026 operating expenses of $380.55M rose 51.7% year over year, behind the +85.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +60.0% a year.
Context
- Operating expenses amounted to 125.5% of revenue in FY2025, down 247.5 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +51.7% toward the trailing-twelve-month pace of +85.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 1.2B USD
- Year-over-year change
- +79.0%
- 4-year CAGR
- +49.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.2B | +79.0% |
| FY2024 | 2024-12-31 | 671.78M | +76.6% |
| FY2023 | 2023-12-31 | 380.5M | +29.6% |
| FY2022 | 2022-12-31 | 293.57M | +21.1% |
| FY2021 | 2021-12-31 | 242.48M | — |
Operating Expenses vs competitors
How MDGL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +85.7% is the 2nd highest of 7, against a peer median of +17.3%.
- Operating expenses amounts to 116.6% of revenue for MDGL, versus a peer median of 3294.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.5B USD | +85.7% | +60.0% | 116.6% | |
| LTM Jun 2026 | $560.02M USD | +163.1% | +77.5% | — | |
| LTM Jun 2026 | $250.97M USD | +6.0% | +32.7% | 3524.4% | |
| LTM Mar 2026 | $152.46M USD | +30.0% | +8.2% | 762.3% | |
| FY2025 | €137.37M EUR | +28.7% | +22.8% | 3064.2% | |
| LTM Mar 2026 | $81.97M USD | -16.5% | +2.5% | 227697.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $48.74M USD | -25.7% | +22.4% | — |
| Peer median (excluding MDGL) | — | +17.3% | +22.6% | 3294.3% | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180.13M | 958.4M |
| Cost of Revenue | 0 | 0 | 0 | 6.23M | 56.15M |
| Gross Profit | 0 | 0 | 0 | 173.9M | 902.26M |
| Gross Margin | — | — | — | 96.5% | 94.1% |
| Research & Development | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Selling, General & Admin | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Operating Expenses | 242.48M | 293.57M | 380.5M | 671.78M | 1.2B |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| EBITDA | (241.44M) | (290.92M) | (360.39M) | (450.13M) | (264.47M) |
| EBITDA Margin | — | — | — | -249.9% | -27.6% |
| Operating Income | (242.48M) | (293.57M) | (380.5M) | (497.88M) | (300.1M) |
| Operating Margin | — | — | — | -276.4% | -31.3% |
| Interest Income | 363K | 2.19M | 19.58M | 46.65M | 37.36M |
| Interest Expense | 0 | 3.96M | 12.71M | 14.67M | 22.31M |
| Other Income / Expenses | 636K | (1.78M) | 6.87M | 31.98M | 11.81M |
| Income Before Tax | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Pre-Tax Margin | — | — | — | -258.6% | -30.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Net Margin | — | — | — | -258.6% | -30.1% |
| EPS (Basic) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| EPS (Diluted) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| Weighted Avg Shares | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
| Weighted Avg Shares (Diluted) | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.